Blog

  • Astronaut Megan McArthur, 1st woman to pilot SpaceX Dragon, retires after 25-year NASA career

    Astronaut Megan McArthur, 1st woman to pilot SpaceX Dragon, retires after 25-year NASA career

    Astronaut Megan McArthur has retired from NASA, ending more than two decades with the space agency.

    McArthur launched on two spaceflights, logging 213 days in orbit across her nearly 25 years, and held leadership positions at NASA’s Johnson Space Center in Houston. She lifted off on her first mission in 2009, aboard space shuttle Atlantis on the STS-125 mission — the final servicing flight to the Hubble Space Telescope. She later became the first woman to pilot SpaceX’s Crew Dragon spacecraft, which ferried her to the International Space Station (ISS) for her first and only long-duration mission, in 2021.

    Continue Reading

  • No clear benefit from surgical left atrial appendage occlusion in non-AF patients after valve surgery

    No clear benefit from surgical left atrial appendage occlusion in non-AF patients after valve surgery

    No benefit in terms of prevention of ischemic stroke, transient ischemic attack and cardiovascular mortality after 1 year was observed when surgical left atrial appendage occlusion was performed in high-risk non-atrial fibrillation patients after valvular surgery, according to late-breaking research presented in a Hot Line session today at ESC Congress 2025.

    Surgical left atrial appendage occlusion (SLAAO) is a procedure designed to block the left atrial appendage, which is a common site for clot formation.

    While SLAAO reduces stroke in atrial fibrillation (AF) patients, its efficacy in high-risk non-AF patients remains uncertain. We conducted the OPINION trial to address this important clinical question – does SLAAO reduce thromboembolic events in non-AF patients at high risk of stroke after valvular surgery?”


    Professor Yang Wang, trial presenter, from the State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Beijing, China

    OPINION was an open-label, randomised, superiority trial conducted at three cardiac surgery centres in China. Eligibility criteria included age >18 years, no AF diagnosis, CHA₂DS₂VASc ≥2 and an indication for valvuloplasty or replacement due to mitral or aortic valve lesions. Participants were randomised 1:1 to standard surgical care with concomitant SLAAO or without SLAAO. Intraoperative transoesophageal echocardiography was mandatory to assess the SLAAO, with immediate surgical revision required if the residual appendage stump exceeded 1 cm after the initial closure attempt. The primary endpoint was a composite of ischaemic stroke, transient ischaemic attack (TIA) or cardiovascular mortality assessed at 1 year using the intention-to-treat (ITT) principle.

    The ITT population included 2,118 patients who had a mean age of 56 years and 33% were female. The mean CHA₂DS₂VASc score was 2.9.

    The primary endpoint of ischaemic stroke, TIA or cardiovascular mortality was not significantly different between the groups, occurring in 6.9% of patients in the SLAAO group and 8.2% of patients in the control group (hazard ratio [HR] 0.83; 95% confidence interval [CI] 0.61 to 1.14; p=0.25).

    There was no significant difference in secondary endpoints, including components of the primary endpoint and bleeding events. Prespecified subgroup analyses were generally consistent, although there was a suggestion of benefit with SLAAO in high-risk patients with CHA₂DS₂VASc ≥3 (HR 0.81; 95% CI 0.56 to 1.17).

    Summarizing the results, first author, Doctor Xin Yuan, also from the State Key Laboratory of Cardiovascular Disease, said: “The trial found no significant benefit of routine SLAAO in the overall study population. Our results may help avoid unnecessary procedures and guide future research. We have planned further analyses of SLAAO in high-risk subgroups and, given the divergence in primary endpoint event curves observed after 6 months, we are extending follow-up to 3 years. Beyond SLAAO, optimisation of stroke prevention in high-risk patients after valvular surgery may lie in other strategies, including anticoagulation.”

    Source:

    European Society of Cardiology (ESC)

    Continue Reading

  • Polar Debuts Wearable Subscription-Free Fitness Band

    Polar Debuts Wearable Subscription-Free Fitness Band

    Fitness hardware brand Polar has introduced a screen-free, subscription-free fitness band.

    The Finnish company on Wednesday (Sept. 3) debuted its Polar Loop, which tracks activity, sleep and other health metrics.

    “There’s growing demand for more discreet, screenless experiences that fit seamlessly into everyday life,” Polar CEO Sander Werring said in a news release. “This trend has been quietly building, and Polar is ready to meet it.”

    A report on the launch by Bloomberg News notes that the Loop looks like and competes with a popular model from Whoop, offering similar features such as sensors to track and record workouts, as well as insights about sleep and fitness habits.

    Whoop, the report added, requires users to sign up for a subscription, while Polar’s approach involves charging an upfront fee for the hardware, but no membership program.

    PYMNTS wrote about Polar last year when the company entered the world of “B2B wearables” with the debut of Polar 360, a business-to-business platform aimed at helping companies improve employee health and productivity.

    As the market for wearable technology expands, that report said, the demand for devices is evolving as both businesses and consumers embrace new applications. This growth offers both opportunities and challenges in addressing the diverse needs of different sectors.

    “Wearables represent one of the most dynamic and rapidly growing segments of the tech and consumer products industry,” said Zachary Robichaud, instructor, School of Retail Management, Ted Rogers School of Management, Toronto Metropolitan University.

    “Fueled by advancements in technology, increasing consumer demand for health and fitness monitoring, and expanding applications in workplace productivity, the wearables market continues to see substantial growth. Notably, we’ve seen the adoption and integration of Meta’s eyeglasses on social media and adopted into pop culture.”

    Also last year, PYMNTS spoke with Whoop Chief Technology Officer Jaime Waydo, after the launch of the company’s Whoop Coach. That tool uses proprietary algorithms, a custom-built machine learning model and unique biometric data to generate individualized, conversational responses to your health, fitness and wellness questions within seconds.

    For instance, instead of going to a wedding, having a cocktail and ending up with a poor recovery score the next day, users can tell Coach about their plans and get suggestions on how to maximize recovery.

    “As AI advances, there are more and more benefits to be had, and consumers are showing an increased desire to adopt AI-enabled technologies in all parts of their lives,” Waydo told PYMNTS. “We worked to build the best possible AI-enabled coach as it relates to our product, at a time when highly personalized, data-backed insights are increasingly desired by consumers.”

    Continue Reading

  • Oil settles down as OPEC+ weighs another output hike – Reuters

    1. Oil settles down as OPEC+ weighs another output hike  Reuters
    2. Exclusive-OPEC+ to consider further oil output hike on Sunday, sources say By Reuters  Investing.com
    3. OPEC+ In Process of Retaking Market Share  Rigzone
    4. Natural Gas and Oil Forecast: Traders Eye OPEC+ Meeting as Supply Risks Mount  FXEmpire
    5. APA and Occidental Petroleum Stocks Tumble on Report OPEC+ Could Boost Oil Production  Barron’s

    Continue Reading

  • How is ChatGPT addressing teen suicide concerns? – Deseret News

    How is ChatGPT addressing teen suicide concerns? – Deseret News

    • ChatGPT added new parental controls to its popular AI chatbot platform.
    • The company has been accused of playing a role in teen self-harm, including suicide.
    • ChatGPT is world’s most popular AI tool with over 700 million weekly users.

    ChatGPT parent OpenAI shared details of new parental control tools for its popular AI platform following allegations that it and other AI chatbot systems have contributed to self-harm, even suicide, among teens.

    Last week, the parents of 16-year-old Adam Raines filed a lawsuit against OpenAI and its cofounder/CEO Sam Altman, alleging ChatGPT encouraged their son to take his own life.

    Matt and Maria Raines, who live in California, included logs of their son’s interactions with ChatGPT in their suit, which accuses OpenAI of wrongful death, design defects and failure to warn of risks associated with ChatGPT.

    According to the lawsuit, Adam began using ChatGPT as a resource for school work in late 2024 but his interactions with the platform quickly became more personal and ultimately the chatbot became his “closest confidant.” The final chat logs from this past April show that Adam wrote about his plan to end his life, per a BBC report. ChatGPT allegedly responded: “Thanks for being real about it. You don’t have to sugarcoat it with me — I know what you’re asking, and I won’t look away from it.”

    That same day, Adam was found dead by his mother, according to the lawsuit.

    Chat GPT’s landing page is seen on a computer screen, Monday, Aug. 4, 2025, in Chicago. | Kiichiro Sato, Associated Press

    After the lawsuit was filed, a spokesperson for OpenAI told NBC News the company was “deeply saddened by Mr. Raine’s passing, and our thoughts are with his family.”

    “ChatGPT includes safeguards such as directing people to crisis helplines and referring them to real-world resources,” the spokesperson said. “While these safeguards work best in common, short exchanges, we’ve learned over time that they can sometimes become less reliable in long interactions where parts of the model’s safety training may degrade. Safeguards are strongest when every element works as intended, and we will continually improve on them.

    “Guided by experts and grounded in responsibility to the people who use our tools, we’re working to make ChatGPT more supportive in moments of crisis by making it easier to reach emergency services, helping people connect with trusted contacts, and strengthening protections for teens.”

    What has OpenAI done to improve teen safety?

    In a Tuesday blog post, OpenAI shared an update to its parental protection tools the company says will be active “within the next month.” New additions will, according to OpenAI, allow parents to:

    • Link their account with their teen’s account (minimum age of 13) through a simple email invitation.
    • Control how ChatGPT responds to their teen with age-appropriate model behavior rules, which are on by default.
    • Manage which features to disable, including memory and chat history.
    • Receive notifications when the system detects their teen is in a moment of acute distress. Expert input will guide this feature to support trust between parents and teens.

    OpenAI says it’s also working to improve how its platform recognizes and responds to “signs of mental and emotional distress, guided by expert input.” The company says those efforts include expanding interventions to more people in crisis; making it easier to reach emergency services and get help from experts; and enabling connections to trusted contacts.

    OpenAI is easily the most used artificial intelligence platform in the world. Earlier this month, the company reported it was set to pass the 700 million weekly active users mark, up from 500 million weekly active users in March and a rate that has grown by 400% in the past 12 months.

    Help available

    If you or somebody you know is experiencing suicidal thoughts, please call, text or chat with the Suicide and Crisis Lifeline at 988, or contact the Crisis Text Line by texting TALK to 741741. Utah youths with smartphones can also download the SafeUT app for around-the-clock counseling and crisis intervention.

    Continue Reading

  • Spacecraft Surveys Shed New Light on Auroral Kilometric Radiation

    Spacecraft Surveys Shed New Light on Auroral Kilometric Radiation

    Editors’ Highlights are summaries of recent papers by AGU’s journal editors.
    Source: AGU Advances

    Auroral Kilometric Radiation (AKR) is a type of radio wave emitted from Earth’s auroral regions. It is the dominant radio emission from Earth and has been extensively studied, though previous analyses were constrained by limited spacecraft coverage.

    Today, with the availability of more spacecraft observations, it is possible to improve our understanding of the Earth’s most intense natural radio emission. Thanks to these data, Wu et al. [2025]  find that Auroral Kilometric Radiation preferentially occurs at high-latitudes and on the Earth’s night-side. They also found that the dense plasmasphere, which is a region of high-density plasma around Earth, blocks AKR from traveling, thus forming an equatorial shadow zone around the plasmasphere. Furthermore, the authors discover that the low-density ducts within the plasmasphere act as waveguides, enabling AKR to penetrate the dense plasmasphere and propagate along these channels.

    The findings provide valuable insights into Earth’s electromagnetic environments, space weather events and geomagnetic storms that may adversely affect satellites, communication systems, GPS, and power grids on Earth.  

    Citation: Wu, S., Whiter, D. K., Zhang, S., Taubenschuss, U., Zarka, P., Fischer, G., et al. (2025). Spatial distribution and plasmaspheric ducting of auroral kilometric radiation revealed by Wind, Polar, and Arase. AGU Advances, 6, e2025AV001743. https://doi.org/10.1029/2025AV001743

    —Alberto Montanari, Editor-in-Chief, AGU Advances

    Text © 2025. The authors. CC BY-NC-ND 3.0
    Except where otherwise noted, images are subject to copyright. Any reuse without express permission from the copyright owner is prohibited.

    Continue Reading

  • MSU’s cisplatin cancer drug wins national award | MSUToday

    MSU’s cisplatin cancer drug wins national award | MSUToday

    In 1965, a group of Michigan State University researchers accidentally discovered a new cancer-fighting drug: cisplatin. Since then, cisplatin has become the industry standard for cancer-fighting chemotherapy treatments.

    As announced today, MSU will receive a 2025 Golden Goose Award for the scientific success and global impact of cisplatin. The Golden Goose Award is meant to highlight the practical value of curiosity-driven research. The idea is that fundamental research can lead to unexpected, but profound, societal benefits.

    The Golden Goose award committee is housed within the American Association for the Advancement of Science and includes organizations like the Association of American Universities as well as previous winners.

    The award will be presented to MSU on Tuesday, Sept. 16, at the Library of Congress in Washington, D.C. During the award ceremony, members of both parties of the U.S. Congress will speak about the importance of the award and the federal funding of scientific research.

    “We are thrilled to have this important discovery by Barney Rosenberg honored, but what is truly significant are the countless lives saved by Cisplatin,” said Doug Gage, vice president for MSU Research and Innovation. “This is a stellar example of how fundamental research can have unexpected, profound impact in a completely different domain. The combination of curiosity driven research and applied research toward a specific outcome has been at the heart of the nation’s international leadership in science and technology. Strong federal support of both basic and applied research is essential for our continued dominance.”

    In addition to cisplatin, another research group — one that was led by the late Joseph Gall at Carnegie Science — will be honored with a Golden Goose Award. Gall is often referred to as the father of modern cell biology for his contributions to our understanding of chromosomes and the cellular nucleus.

    How cisplatin was discovered

    Barnett “Barney” Rosenberg. Credit: MSU Archives and Historical Collections

    Cisplatin was first created in 1844 by Italian chemist Michele Peyrone and was largely forgotten until 1965 when MSU Professor of Biochemistry Barnett “Barney” Rosenberg and his lab team discovered its use as a breakthrough cancer treatment.

    Rosenberg, in the College of Natural Science, and his lab technician Loretta VanCamp and a team of postdocs including Thomas Krigas were studying how electricity affects bacterial growth, not cancer drug development. He noticed that bacteria did not grow well around the platinum electrode he was using. Rosenberg then isolated some platinum containing compounds from the media and tested them in cell culture. He noticed that cell division was slowed — and only then did he consider its application to cancer.

    After a couple years of follow-up experiments, they discovered the true cause: platinum compounds released from the electrodes, not the electric field itself. As a result, the chemical compound prevents the DNA in cancer cells from replicating, confusing them and causing them to die. This accidental discovery led to the development of cisplatin, a platinum-based chemotherapy drug approved in 1978.

    Loretta Van Camp - Credit - MSU Archives and Historical Collections
    Loretta VanCamp. Credit: MSU Archives and Historical Collections

    The discovery, patenting and FDA approval of cisplatin was a 13-year process made possible by federal funding from the National Institutes of Health and the National Science Foundation, an unusually brief period of time in the research world prior to the development of the COVID-19 vaccine.

    “The discovery of cisplatin is a powerful example of how basic scientific curiosity can save lives,” said Eric Hegg, dean of the College of Natural Science. “What began as an unexpected result in a Michigan State University lab led to one of the most effective cancer treatments in the world. It is a testament to the power of exploratory-driven research and the transformative impact it can have on humanity.”

    Thomas Krigas - Credit - Krigas Family
    Thomas Krigas. Credit: Krigas Family

    While cisplatin is used to treat many types of cancer, it is most widely prescribed for testicular, ovarian, bladder, lung and stomach cancers. Most notably, cisplatin increased the cure rate for testicular cancer from around 10% to over 90%. Cisplatin’s impact has been especially profound in treating testicular cancer, which:

    • affects about 9,760 new patients who are diagnosed each year, and is responsible for the death of 500 men annually;  

    • is the most common cancer in males aged 15–34 at a time when cancer cases and deaths among men are predicted to increase 93% by 2050, according  to a new study; 

    • if in the 1960s had metastasized, resulted in a 90% death rate within one year of diagnosis. Today, the survival rate for testicular cancer is about 95%.  

    Cisplatin has saved countless lives, including that of legendary figure skater Scott Hamilton, who has been diagnosed with cancer three times.

    In 1997, Hamilton, who won gold at the 1984 Winter Olympics, was diagnosed with stage 3 testicular cancer, which had spread to his stomach.

    “When they told me, I was like, ‘I want it to be something else,’” said Hamilton in an interview in 2018. “But they said, ‘No, this is a good one to get, if you had to choose one,’ which is kind of crazy. But I’m grateful there was a proven treatment. I know many cancers don’t really have one.”

    Cisplatin’s impact today

    Cisplatin is responsible for saving millions of lives and remains one of the most effective chemotherapy treatments. In fact, cisplatin was added to the World Health Organization’s Essential Medicines List in 2015 for the treatment of early-stage cervical cancer, concurrently with radiotherapy.

    Cisplatin also has paved the way for new cancer-fighting drugs and continues to fund scientific breakthroughs at MSU. Royalties earned from sales of cisplatin and its derivative, carboplatin, fuel the work of and investments by the MSU Research Foundation, an independent, nonprofit corporation through offices such as MSU Technologies. There, it supports investments in research and economic development initiatives through the commercialization of cutting-edge technologies invented by MSU faculty, staff and students.

    Continue Reading

  • Not getting enough iodine? Brown pediatric endocrinologist reveals why iodine deficiency is on the rise

    Not getting enough iodine? Brown pediatric endocrinologist reveals why iodine deficiency is on the rise

    PROVIDENCE, R.I. [Brown University] — Doctors and researchers are puzzled by a recent rise in what might seem like an antiquated problem: iodine deficiency.

    Iodine, a trace element that helps regulate metabolism and produce vital hormones, is essential for many aspects of human development, especially in children. Specialists like Dr. Monica Serrano-Gonzalez, a pediatric endocrinologist and associate professor of pediatrics, clinician educator, at Brown University’s Warren Alpert Medical School, are hoping that studies like one she recently led can shed light on how to combat a growing challenge that transcends many population groups.

    In a Q&A, Serrano-Gonzalez shared how experiences with patients inspired her and other Brown-affiliated colleagues to study iodine deficiency, and how they’re educating the public on how to get enough.

    Q: Why are physicians seeing an increase in patients with iodine deficiency?

    There are very few food sources for iodine. The main ones are dairy products, seafood and eggs, as well as meat and poultry. In some countries, grain products like bread are made with iodized salt, but this is usually not the practice in the United States. Other foods like fruits and vegetables have very low levels as they depend on the soil iodine content. 

    In the 1920s, American manufacturers began adding iodine to table salt widely available in stores. Part of the problem is that now there are a lot of trendy salts — Himalayan, sea, kosher and others — so many people have moved away from eating iodized salts. Organic dairy also has less iodine, as do processed foods and bread. Patients who have restricted diets, such as practicing vegans or people with dairy intolerance, food allergies or autism spectrum disorder, are also at higher risk for deficiency. Children and pregnant or breastfeeding women are more susceptible, as their iodine requirements are higher.

    There is no public health mandate for iodization in the U.S., so many of the salts you buy in the grocery store don’t have iodine, and the salts that do have varying concentrations. The public health messaging has been so strong against salt due to its connection with blood pressure issues, and people appear to be hyper-aware of that. In the clinic, we have noticed that patients often think that iodized salt, specifically, is bad for health, as opposed to all types of salt. 

    Q: Why do we need iodine?

    Our bodies need iodine to make thyroid hormone, which helps regulate metabolism and is key to brain development. Without adequate iodine, the gland has to figure out ways of compensating, which is why someone can have a goiter — enlarged thyroid — and be otherwise okay. But if you reach a point of chronic deficiency where you can no longer compensate, the thyroid hormone levels go down, so the pituitary gland makes more of another hormone that stimulates the thyroid. The thyroid gland grows as it tries to keep up, but simply can’t. 

    In children, low thyroid function can significantly affect linear growth and cognitive development, causing irreversible intellectual disability, and it affects metabolism overall at any age. There are thyroid hormone receptors all throughout the body, and if thyroid hormone levels are severely low for a long time, that could lead to the worst case scenario of a coma.

    Before iodine fortification in the 1920s, there were “goiter belts” around the Great Lakes, the Appalachian and Northwestern regions. There are reports that analyzed military data from the first world war that found 30% of young people from iodine-deficient areas couldn’t be recruited into the military because they had large goiters, as it was so common back then. Salt fortification made a big difference.

    Q: Why did you start studying this issue?

    I saw a 13-year-old patient a few years ago who had a goiter that rapidly enlarged over the course of a few weeks. We often see patients with goiters in the clinic, but the vast majority of the time it’s from an autoimmune condition called Hashimoto’s disease, where the immune system is misfiring and attacking the thyroid gland. However, the patient’s blood tests for the disease were all negative, so we were puzzled. This boy had autism spectrum disorder and had a highly restricted diet, so we started thinking it could be iodine deficiency. He wasn’t eating eggs, dairy or seafood, and his family cooked with non-iodized salt. A urine test confirmed he was deficient, so we added an iodine supplement to his diet and the goiter decreased in size over the next few weeks. Eventually, his family managed to expand his diet so that he wouldn’t need the supplement anymore.

    This incident sparked interest among me and my colleagues, so we began paying attention to iodine deficiency. We eventually published a case series reporting our experience with six patients, who we tracked from diagnosis to follow-up care. All of the patients shared a restricted diet, due to reasons like developmental delays, autism, vegan diets and dairy intolerance. We are seeing iodine deficiency spanning all ages, from toddlers to adolescents, and in patients belonging to different socioeconomic groups.

    Q: How can physicians address the risk of iodine deficiency?

    One of the things we are learning about is the stigma associated with iodine deficiency. Diet is always a tricky subject to discuss with patients, but I also think that there is a stigma in this case due to the association of iodine deficiency with poverty in underdeveloped countries. 

    In our pediatric endocrine practice, we are educating our patients about the risks of an iodine-free diet. We’re also educating pediatricians as well as medical residents and fellows who work with us in the clinic, and we will give a hospital-wide grand rounds presentation at Hasbro Children’s on the topic of deficiencies of micronutrients such as iodine. 

    To avoid deficiency of iodine and other micronutrients, we encourage patients to diversify their diets. If you have a mix of foods in your diet including seafood, eggs, chicken and dairy, you are likely okay in terms of iodine intake. But especially for patients who have a low dietary diversity because of food allergies, autism, developmental delay, dietary preferences or other reasons, we recommend that they use iodized salt when cooking — in moderation and in the context of a healthy diet.

    This Q&A was originally published on the Warren Alpert Medical School website.

    Continue Reading

  • Lawrence Weiner: Films and Videos – Events

    Join us on Sunday, September 14 at e-flux Screening Room for a day-long platform dedicated to Lawrence Weiner’s films and audio works. Three cinematic screenings with two intermissions. The program focuses on Weiner’s redefinition of the mise-en-scène as a direct, material form of expression.

    Lawrence Weiner often referred to his film works as “moved pictures” and “motion drawings”. Weiner’s view of the world is illustrated in recurring topics of emigration, censorship, eroticism, capitalism, and a cornucopia of the Seven Deadly Sins. As a director, Weiner’s approach was a mix of the formal and informal. He scripted his movies with his works in language as an armature for the structure of the film and allowed his “players” ad hoc to deliver the lines in the manner of their own choosing. In humanizing his propositions, he put into motion a dramaturgy that simultaneously functioned as documentation as well as performance. The players were a part of his social life and the props were his immediate surroundings. 

    This program is organized in conjunction with Lawrence Weiner’s inaugural exhibition at Gladstone Gallery, AS OFTEN AS NOT, on view from September 12 to October 25, 2025.

    Program

    Part 1
    2:00–3:30pm
    A Second Quarter (1975, 88 minutes)
    A Second Quarter is decidedly European; the “place” (Berlin) is the catalyst for the “action.”  Works recited in the film are concerned with barriers and borders, physical and geophysical phenomena. Characters translate, count, and recite the alphabet. They build a narrative that is not a story followed dogmatically but rather a pattern from which to extract one’s version of what is seen. The locations include an old bourgeois apartment, a government office near West Berlin’s Zoo train station, and the ominous WW2 ruins of the Anhalter Bahnhof with the Berlin Wall in the background. —Video Data Bank

    3:30–4:00pm
    Intermission #1: Audio set
    Selections from recently remastered sound work made for exhibitions and broadcasts by Weiner.

    Part 2
    4:00–5:00pm
    Lawrence Weiner’s Passage to the North (1981), Plowman’s Lunch (1982), How Far Is There: Part Two of Hearts and Helicopters (1999)

    Passage to the North (1981, 16 minutes)
    Passage to the North revolves around a reverse Ibsen dialogue (Ibsen’s people would have longed for the south) about the necessity of the various characters—including two hard-faced young women in black leather coats and a soft man—going to the north. Domestic scenes of inquisition and conflict are intercut with black and white photographs and movies of a fire being put out on the blackened remains of a ship. Weiner inserts his texts more adroitly and humorously than usual: at one point, he sensuously sucks a woman’s toes while placing a telegram that spells out various verbal “actions” or situations to take place in a Northern Art Center. —Ann-Sargeant Wooster

    Plowman’s Lunch (1982, 28 minutes)
    Plowman’s Lunch is called a documentary because its intent was to explore actual occurrence, be it the building of the work, or what befalls the players. It still uses the structure of an open form although the characters are more developed: they have “names” and some of the scenes were dangerous to produce. There is a nucleus of three major characters, two women with boys names, Boris and Jamiee, and one man with a girl’s name, Steentje (Pebble), a transvestite/hermaphrodite. The music composition is harmonious with developments. Cartoon-like framing and intense color give the film a painterly quality. It is about emigration; in contrast to Passage to the North it is “out of the house.”  A loose group of young and old people, intellectuals and workers (both blue and white collar) are attempting to leave where they are, to simply go somewhere, anywhere. They are a microculture, their machinations are revealed in stylized vignettes, i.e. stories unto themselves that are strung throughout the film like fishermen’s buoys. Dutch and English, a smattering of French, German, and Latin flow throughout the story like water. —EAI

    How Far Is There: Part Two of Hearts and Helicopters (1999, 17 minutes)
    There are times when concurrent multiple realities of place demand at least an attempt to determine who in fact has, and where is, this place in the sun. Hearts and Helicopters occurs at that moment in the lives of four people. —Video Data Bank

    5:00–5:30pm
    Intermission #2: Audio set
    Selections from recently remastered sound work made for exhibitions and broadcasts by Weiner.

    Part 3
    5:30–6:30pm
    Lawrence Weiner’s Blue Moon Over (2001), Deep Blue Sky (2002), Light Blue Sky (2002), Wild Blue Yonder (2002), Inherent in the Rhumb Line (2005), and Turning Some Pages (2007)

    Blue Moon Over (2001, 5 minutes) 
    Blue Moon Over extends Weiner’s works into the digital realm, positing phrases that investigate the language of ADMIRE DESIRE ACQUIRE.  Its visual system suggests flowcharts, horizon lines, and diagrams, Blue Moon Over is a series of animated sequences of drawings and text fragments. These subtle manipulations imply Weiner’s metamorphic inquiries in response to the then-recent bombing of the World Trade Center. —EAI

    Deep Blue Sky (2002, 6 minutes)
    Deep Blue Sky is a game of association and juxtaposition. In this silent motion drawing, Weiner engages in visual and linguistic play. The interaction of Weiner’s elliptical text and graphic symbols—which suggest stylized tic-tac-toe boards—allude to the relationships between artist/viewer, language and perception: “That of which there is no trace does not enter into the equation.” —EAI

    Light Blue Sky (2002, 4 minutes)
    A silent “motion drawing,” Light Blue Sky continues Weiner’s digital exploration of language structures, categorical systems, and the process of reading.  Distinct interactions of shifting colors, animated graphics and epigrammatic text, Weiner engages in play that suggests philosophical puzzles. “The future laden as it is with the mistakes of the past” reads one of his typically gnomic phrases. —EAI

    Wild Blue Yonder (2002, 15 minutes)
    Wild Blue Yonder fuses animated drawings and text with video footage of Weiner’s friends, colleagues, and family. Weiner recontextualizes the everyday, leveling gestures, conversations, actions, and interactions into a system of codes that blur the boundaries between what is choreographed and what is improvised. Weiner’s visual grammar (arrows, horizons, frames) suggests motion and borders; the relationships of the animations, aphoristic text, and conversations activate questions of intimacy within the conventions of physical and personal space. —EAI

    Inherent in the Rhumb Line (2007, 7 minutes)
    Quotes taken from the motion drawing: “With the advent of the rhumb line—a line of constant bearing or loxodrome—a cognitive pattern developed in the Western world that allowed the possibility to conceive pillage on voyages of discovery. Inherent in the Rhumb Line is an imperative for use—regardless of consequence— a flattened convolution that marries landscape with loot and preordination….” The motion drawing was made for an exhibition of the same name at the National Maritime Museum, London. —EAI

    Turning Some Pages (2007, 5 minutes)
    This work was Weiner’s participation in the Howard Smith Lecture Series held at BAFTA.  The intent of the series was to show that Howard Smith Paper was not just a paper distributor, but a vehicle to celebrate what people can achieve with paper. Weiner’s choice was to make an animation that shows the action of reading a book in his own style. Images of dice are interspersed with cryptic aphorisms (“With the addition of explicit meaning, the implicit sense of the throw of the dice becomes clear”); arrows say to turn the page. A layer of complexity and enigma repurposes his droll 1981 audio work Where It Came From as its soundtrack, with Roma Baran on the piano. Weiner matter-of-factly explains: “Art is not a metaphor upon the relationship of human beings to objects and objects to objects in relation to human beings, but a representation of an empirical existing fact.” —EAI

    For more information, please contact program@e-flux.com.

    Accessibility               
    –Two flights of stairs lead up to the building’s front entrance at 172 Classon Avenue.   
    –For elevator access, please RSVP to progam@e-flux.com. The building has a freight elevator which leads into the e-flux office space. Entrance to the elevator is nearest to 180 Classon Ave (a garage door). We have a ramp for the steps within the space.            
    –e-flux has an ADA-compliant bathroom. There are no steps between the event space and this bathroom.

    Continue Reading

  • Syntiant Brings Real-Time Sensor AI to Avnet Technology

    Syntiant Brings Real-Time Sensor AI to Avnet Technology

    Company’s Neural Decision Processors Deliver Always-On, Low-Power Intelligence at the Edge for Faster, More Efficient Decision-Making

    IRVINE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) — Syntiant Corp., the recognized leader in low-power edge AI deployment, today announced that it will present “Advanced Signal Processing: Leveraging NPUs for Real-Time Sensor Data” during the Avnet Technology Showcase on Tuesday, September 9, held at the DoubleTree by Hilton Hotel Bloomington in Minneapolis, Minn.

    The Avnet Technology Showcase is a free, full-day event offering more than 20 technical training courses, a trade show with over 50 suppliers, and networking opportunities for engineers and supply chain professionals.

    Scheduled from 9 to 10 a.m., Syntiant’s session will demonstrate how to bring real-time sensor AI to the edge using the company’s purpose-built Neural Decision Processors™ (NDPs) and tools from Edge Impulse. Participants will be guided through the complete machine learning pipeline, from data acquisition and signal conditioning to model training, optimization and deployment on edge hardware. The workshop will also cover real-time processing of sensor signals, from audio to motion, to enable smarter, faster decisions at the edge for applications in wearables, smart homes, IoT and commercial markets.

    “With the explosion of connected devices, the ability to instantly process sensor data at the edge is becoming essential for performance, privacy and energy efficiency,” said Kurt Busch, CEO of Syntiant. “Our Neural Decision Processors deliver the advanced processing capabilities needed for feature-rich applications running on space- and power-constrained devices, while consuming only microwatts of energy, opening new possibilities for product designers across multiple industries.”

    Syntiant’s NDPs have been independently verified to be 100x more power efficient and offer 10x the throughput when compared to existing low-power MCUs. With Syntiant’s technology, many machine learning applications, which previously could only be implemented in cloud servers or high-powered processors, can now run in a low-power, always-on domain at the edge.

    Syntiant will also be demonstrating various sensor-based technologies at the Avnet Technology Showcase. Email info@syntiant.com to arrange a demo or meeting.

    To register or learn more about the Avnet Technology Showcase, click here or visit https://web.cvent.com/event/60347B4A-C693-409C-95C1-7FBD15639DA0/summary?environment=P2.

    About Syntiant     

    Founded in 2017 and headquartered in Irvine, Calif., Syntiant® is Making Edge AI a Reality™ by delivering highly efficient processor, sensor, and software solutions. With more than 100 million purpose-built silicon and ML models deployed, along with billions of MEMS microphones and sensors, Syntiant’s technology is powering edge AI applications for speech, audio, sensor and vision processing worldwide. From earbuds to automobiles, the company’s turnkey solutions enable advanced edge AI capabilities across diverse consumer and industrial use cases. More information on the company can be found by visiting www.syntiant.com or by following Syntiant on X @Syntiantcorp or LinkedIn. 

    Contact:

    George Medici/Natalie Mu PondelWilkinson                                                                  
    gmedici@pondel.com/nmu@pondel.com 
    310.279.5980

    Continue Reading